Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1996 Jun 25;93(13):6802–6807. doi: 10.1073/pnas.93.13.6802

Inverse agonism of histamine H2 antagonist accounts for upregulation of spontaneously active histamine H2 receptors.

M J Smit 1, R Leurs 1, A E Alewijnse 1, J Blauw 1, G P Van Nieuw Amerongen 1, Y Van De Vrede 1, E Roovers 1, H Timmerman 1
PMCID: PMC39108  PMID: 8692899

Abstract

Histamine H2 receptors transfected in Chinese hamster ovary (CHO) cells are time- and dose-dependently upregulated upon exposure to the H2 antagonists cimetidine and ranitidine. This effect appears to be H2 receptor-mediated as no change in receptor density was observed after H1 or H3 antagonist treatment or after incubation with the structural analogue of cimetidine, VUF 8299, which has no H2 antagonistic effects. By using transfected CHO cells expressing different densities of wild-type H2 receptors or an uncoupled H2Leu124Ala receptor, the histamine H2 receptor was found to display considerable agonist-independent H2 receptor activity. Cimetidine and ranitidine, which both induce H2 receptor upregulation, actually functioned as inverse agonists in those cell lines displaying spontaneous agonist-independent H2 receptor activity. Burimamide, on the other hand, was shown to act as a neutral antagonist and did as expected not induce H2 receptor upregulation after long-term exposure. The displayed inverse agonism of H2 antagonists appears to be a mechanistic basis for the observed H2 antagonist-induced H2 receptor upregulation in transfected CHO cells. These observations shed new light on the pharmacological classification of the H2 antagonists and may offer a plausible explanation for the observed development of tolerance after prolonged clinical use.

Full text

PDF
6802

Images in this article

6805Fig. 3
on p.6805

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adie E. J., Milligan G. Agonist regulation of cellular Gs alpha-subunit levels in neuroblastoma x glioma hybrid NG108-15 cells transfected to express different levels of the human beta 2 adrenoceptor. Biochem J. 1994 Jun 15;300(Pt 3):709–715. doi: 10.1042/bj3000709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Adie E. J., Milligan G. Regulation of basal adenylate cyclase activity in neuroblastoma x glioma hybrid, NG108-15, cells transfected to express the human beta 2 adrenoceptor: evidence for empty receptor stimulation of the adenylate cyclase cascade. Biochem J. 1994 Nov 1;303(Pt 3):803–808. doi: 10.1042/bj3030803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Arima N., Kinoshita Y., Nakamura A., Yamashita Y., Chiba T. Homologous desensitization of histamine H2 receptors in the human gastric carcinoma cell line MKN-45. Am J Physiol. 1993 Nov;265(5 Pt 1):G987–G992. doi: 10.1152/ajpgi.1993.265.5.G987. [DOI] [PubMed] [Google Scholar]
  4. Barker E. L., Westphal R. S., Schmidt D., Sanders-Bush E. Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem. 1994 Apr 22;269(16):11687–11690. [PubMed] [Google Scholar]
  5. Baxter G. S., Tilford N. S. Endogenous ligands and inverse agonism. Trends Pharmacol Sci. 1995 Aug;16(8):258–259. doi: 10.1016/s0165-6147(00)89038-0. [DOI] [PubMed] [Google Scholar]
  6. Black J. W., Duncan W. A., Durant C. J., Ganellin C. R., Parsons E. M. Definition and antagonism of histamine H 2 -receptors. Nature. 1972 Apr 21;236(5347):385–390. doi: 10.1038/236385a0. [DOI] [PubMed] [Google Scholar]
  7. Bond R. A., Leff P., Johnson T. D., Milano C. A., Rockman H. A., McMinn T. R., Apparsundaram S., Hyek M. F., Kenakin T. P., Allen L. F. Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor. Nature. 1995 Mar 16;374(6519):272–276. doi: 10.1038/374272a0. [DOI] [PubMed] [Google Scholar]
  8. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  9. Breitner J. C., Welsh K. A., Helms M. J., Gaskell P. C., Gau B. A., Roses A. D., Pericak-Vance M. A., Saunders A. M. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging. 1995 Jul-Aug;16(4):523–530. doi: 10.1016/0197-4580(95)00049-k. [DOI] [PubMed] [Google Scholar]
  10. Coruzzi G., Bertaccini G. Increased parietal cell sensitivity after chronic treatment with ranitidine in the conscious cat. Agents Actions. 1989 Nov;28(3-4):215–217. doi: 10.1007/BF01967404. [DOI] [PubMed] [Google Scholar]
  11. Cotecchia S., Exum S., Caron M. G., Lefkowitz R. J. Regions of the alpha 1-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function. Proc Natl Acad Sci U S A. 1990 Apr;87(8):2896–2900. doi: 10.1073/pnas.87.8.2896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. De Lean A., Stadel J. M., Lefkowitz R. J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem. 1980 Aug 10;255(15):7108–7117. [PubMed] [Google Scholar]
  13. Deakin M., Williams J. G. Histamine H2-receptor antagonists in peptic ulcer disease. Efficacy in healing peptic ulcers. Drugs. 1992 Nov;44(5):709–719. doi: 10.2165/00003495-199244050-00003. [DOI] [PubMed] [Google Scholar]
  14. Deutsch S. I., Rosse R. B., Kendrick K. A., Fay-McCarthy M., Collins J. P., Jr, Wyatt R. J. Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data. Clin Neuropharmacol. 1993 Dec;16(6):518–524. [PubMed] [Google Scholar]
  15. Diaz J., Vizuete M. L., Traiffort E., Arrang J. M., Ruat M., Schwartz J. C. Localization of the histamine H2 receptor and gene transcripts in rat stomach: back to parietal cells. Biochem Biophys Res Commun. 1994 Feb 15;198(3):1195–1202. doi: 10.1006/bbrc.1994.1169. [DOI] [PubMed] [Google Scholar]
  16. Fukushima Y., Oka Y., Katagiri H., Saitoh T., Asano T., Ishihara H., Matsuhashi N., Kodama T., Yazaki Y., Sugano K. Desensitization of canine histamine H2 receptor expressed in Chinese hamster ovary cells. Biochem Biophys Res Commun. 1993 Feb 15;190(3):1149–1155. doi: 10.1006/bbrc.1993.1170. [DOI] [PubMed] [Google Scholar]
  17. Ganellin R. 1980 Award in Medicinal Chemistry: Medicinal chemistry and dynamic structure-activity analysis in the discovery of drugs acting at histamine H2 receptors. J Med Chem. 1981 Aug;24(8):913–920. doi: 10.1021/jm00140a001. [DOI] [PubMed] [Google Scholar]
  18. Gantz I., Munzert G., Tashiro T., Schäffer M., Wang L., DelValle J., Yamada T. Molecular cloning of the human histamine H2 receptor. Biochem Biophys Res Commun. 1991 Aug 15;178(3):1386–1392. doi: 10.1016/0006-291x(91)91047-g. [DOI] [PubMed] [Google Scholar]
  19. Gantz I., Schäffer M., DelValle J., Logsdon C., Campbell V., Uhler M., Yamada T. Molecular cloning of a gene encoding the histamine H2 receptor. Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):429–433. doi: 10.1073/pnas.88.2.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Götze K., Jakobs K. H. Unoccupied beta-adrenoceptor-induced adenylyl cyclase stimulation in turkey erythrocyte membranes. Eur J Pharmacol. 1994 Jul 15;268(2):151–158. doi: 10.1016/0922-4106(94)90184-8. [DOI] [PubMed] [Google Scholar]
  21. Hanf R., Li Y., Szabo G., Fischmeister R. Agonist-independent effects of muscarinic antagonists on Ca2+ and K+ currents in frog and rat cardiac cells. J Physiol. 1993 Feb;461:743–765. doi: 10.1113/jphysiol.1993.sp019539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kaminsky R., Moriarty T. M., Bodine J., Wolf D. E., Davidson M. Effect of famotidine on deficit symptoms of schizophrenia. Lancet. 1990 Jun 2;335(8701):1351–1352. doi: 10.1016/0140-6736(90)91237-5. [DOI] [PubMed] [Google Scholar]
  23. Kenakin T. Pharmacological proteus? Trends Pharmacol Sci. 1995 Aug;16(8):256–258. doi: 10.1016/s0165-6147(00)89037-9. [DOI] [PubMed] [Google Scholar]
  24. Kim G. D., Carr I. C., Milligan G. Detection and analysis of agonist-induced formation of the complex of the stimulatory guanine nucleotide-binding protein with adenylate cyclase in intact wild-type and beta 2-adrenoceptor-expressing NG108-15 cells. Biochem J. 1995 May 15;308(Pt 1):275–281. doi: 10.1042/bj3080275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kjelsberg M. A., Cotecchia S., Ostrowski J., Caron M. G., Lefkowitz R. J. Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J Biol Chem. 1992 Jan 25;267(3):1430–1433. [PubMed] [Google Scholar]
  26. Leeb-Lundberg L. M., Mathis S. A., Herzig M. C. Antagonists of bradykinin that stabilize a G-protein-uncoupled state of the B2 receptor act as inverse agonists in rat myometrial cells. J Biol Chem. 1994 Oct 21;269(42):25970–25973. [PubMed] [Google Scholar]
  27. Lefkowitz R. J., Cotecchia S., Samama P., Costa T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci. 1993 Aug;14(8):303–307. doi: 10.1016/0165-6147(93)90048-O. [DOI] [PubMed] [Google Scholar]
  28. Leurs R., Smit M. J., Menge W. M., Timmerman H. Pharmacological characterization of the human histamine H2 receptor stably expressed in Chinese hamster ovary cells. Br J Pharmacol. 1994 Jul;112(3):847–854. doi: 10.1111/j.1476-5381.1994.tb13157.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Leurs R., Smit M. J., Timmerman H. Molecular pharmacological aspects of histamine receptors. Pharmacol Ther. 1995 Jun;66(3):413–463. doi: 10.1016/0163-7258(95)00006-3. [DOI] [PubMed] [Google Scholar]
  30. Leurs R., Traiffort E., Arrang J. M., Tardivel-Lacombe J., Ruat M., Schwartz J. C. Guinea pig histamine H1 receptor. II. Stable expression in Chinese hamster ovary cells reveals the interaction with three major signal transduction pathways. J Neurochem. 1994 Feb;62(2):519–527. doi: 10.1046/j.1471-4159.1994.62020519.x. [DOI] [PubMed] [Google Scholar]
  31. Lohse M. J. Molecular mechanisms of membrane receptor desensitization. Biochim Biophys Acta. 1993 Nov 7;1179(2):171–188. doi: 10.1016/0167-4889(93)90139-g. [DOI] [PubMed] [Google Scholar]
  32. Lundell L., Backman L., Ekström P., Enander L. K., Falkmer S., Fausa O., Grimelius L., Havu N., Lind T., Lönroth H. Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol. 1991 Mar;26(3):248–256. doi: 10.3109/00365529109025038. [DOI] [PubMed] [Google Scholar]
  33. Martínez-Mir M. I., Pollard H., Moreau J., Traiffort E., Ruat M., Schwartz J. C., Palacios J. M. Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models. Synapse. 1993 Nov;15(3):209–220. doi: 10.1002/syn.890150306. [DOI] [PubMed] [Google Scholar]
  34. Merki H. S., Wilder-Smith C. H. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology. 1994 Jan;106(1):60–64. doi: 10.1016/s0016-5085(94)94341-9. [DOI] [PubMed] [Google Scholar]
  35. Mewes T., Dutz S., Ravens U., Jakobs K. H. Activation of calcium currents in cardiac myocytes by empty beta-adrenoceptors. Circulation. 1993 Dec;88(6):2916–2922. doi: 10.1161/01.cir.88.6.2916. [DOI] [PubMed] [Google Scholar]
  36. Mezey E., Palkovits M. Localization of targets for anti-ulcer drugs in cells of the immune system. Science. 1992 Dec 4;258(5088):1662–1665. doi: 10.1126/science.1333642. [DOI] [PubMed] [Google Scholar]
  37. Milligan G., Bond R. A., Lee M. Inverse agonism: pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol Sci. 1995 Jan;16(1):10–13. doi: 10.1016/s0165-6147(00)88963-4. [DOI] [PubMed] [Google Scholar]
  38. Molinari S. P., Kaminski R., Di Rocco A., Yahr M. D. The use of famotidine in the treatment of Parkinson's disease: a pilot study. J Neural Transm Park Dis Dement Sect. 1995;9(2-3):243–247. doi: 10.1007/BF02259665. [DOI] [PubMed] [Google Scholar]
  39. Nielsen H. J., Nielsen H., Jensen S., Moesgaard F. Ranitidine improves postoperative monocyte and neutrophil function. Arch Surg. 1994 Mar;129(3):309–315. doi: 10.1001/archsurg.1994.01420270087019. [DOI] [PubMed] [Google Scholar]
  40. Nwokolo C. U., Smith J. T., Gavey C., Sawyerr A., Pounder R. E. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther. 1990;4 (Suppl 1):29–45. [PubMed] [Google Scholar]
  41. Nwokolo C. U., Smith J. T., Sawyerr A. M., Pounder R. E. Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade. Gut. 1991 Dec;32(12):1455–1460. doi: 10.1136/gut.32.12.1455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Ren Q., Kurose H., Lefkowitz R. J., Cotecchia S. Constitutively active mutants of the alpha 2-adrenergic receptor. J Biol Chem. 1993 Aug 5;268(22):16483–16487. [PubMed] [Google Scholar]
  43. Ruat M., Traiffort E., Arrang J. M., Leurs R., Schwartz J. C. Cloning and tissue expression of a rat histamine H2-receptor gene. Biochem Biophys Res Commun. 1991 Sep 30;179(3):1470–1478. doi: 10.1016/0006-291x(91)91738-x. [DOI] [PubMed] [Google Scholar]
  44. Ruat M., Traiffort E., Bouthenet M. L., Schwartz J. C., Hirschfeld J., Buschauer A., Schunack W. Reversible and irreversible labeling and autoradiographic localization of the cerebral histamine H2 receptor using [125I]iodinated probes. Proc Natl Acad Sci U S A. 1990 Mar;87(5):1658–1662. doi: 10.1073/pnas.87.5.1658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Samama P., Cotecchia S., Costa T., Lefkowitz R. J. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem. 1993 Mar 5;268(7):4625–4636. [PubMed] [Google Scholar]
  46. Samama P., Pei G., Costa T., Cotecchia S., Lefkowitz R. J. Negative antagonists promote an inactive conformation of the beta 2-adrenergic receptor. Mol Pharmacol. 1994 Mar;45(3):390–394. [PubMed] [Google Scholar]
  47. Schütz W., Freissmuth M. Reverse intrinsic activity of antagonists on G protein-coupled receptors. Trends Pharmacol Sci. 1992 Oct;13(10):376–380. doi: 10.1016/0165-6147(92)90116-n. [DOI] [PubMed] [Google Scholar]
  48. Smit M. J., Leurs R., Shukrula S. R., Bast A., Timmerman H. Rapid desensitization of the histamine H2 receptor on the human monocytic cell line U937. Eur J Pharmacol. 1994 Dec 15;288(1):17–25. doi: 10.1016/0922-4106(94)90005-1. [DOI] [PubMed] [Google Scholar]
  49. Smit M. J., Roovers E., Timmerman H., van de Vrede Y., Alewijnse A. E., Leurs R. Two distinct pathways for histamine H2 receptor down-regulation. H2 Leu124 --> Ala receptor mutant provides evidence for a cAMP-independent action of H2 agonists. J Biol Chem. 1996 Mar 29;271(13):7574–7582. doi: 10.1074/jbc.271.13.7574. [DOI] [PubMed] [Google Scholar]
  50. Smit M. J., Timmerman H., Alewijnse A. E., Punin M., van den Nieuwenhof I., Blauw J., van Minnen J., Leurs R. Visualization of agonist-induced internalization of histamine H2 receptors. Biochem Biophys Res Commun. 1995 Sep 25;214(3):1138–1145. doi: 10.1006/bbrc.1995.2404. [DOI] [PubMed] [Google Scholar]
  51. Tiberi M., Caron M. G. High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype. J Biol Chem. 1994 Nov 11;269(45):27925–27931. [PubMed] [Google Scholar]
  52. Traiffort E., Ruat M., Arrang J. M., Leurs R., Piomelli D., Schwartz J. C. Expression of a cloned rat histamine H2 receptor mediating inhibition of arachidonate release and activation of cAMP accumulation. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2649–2653. doi: 10.1073/pnas.89.7.2649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Traiffort E., Vizuete M. L., Tardivel-Lacombe J., Souil E., Schwartz J. C., Ruat M. The guinea pig histamine H2 receptor: gene cloning, tissue expression and chromosomal localization of its human counterpart. Biochem Biophys Res Commun. 1995 Jun 15;211(2):570–577. doi: 10.1006/bbrc.1995.1851. [DOI] [PubMed] [Google Scholar]
  54. Westphal R. S., Sanders-Bush E. Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists. Mol Pharmacol. 1994 Nov;46(5):937–942. [PubMed] [Google Scholar]
  55. Wilder-Smith C. H., Ernst T., Gennoni M., Zeyen B., Halter F., Merki H. S. Tolerance to oral H2-receptor antagonists. Dig Dis Sci. 1990 Aug;35(8):976–983. doi: 10.1007/BF01537246. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES